Clinical Trials Browser

Phase 1 × Completed × copanlisib × Clear all

NCT02705859 2026-04-13

Panther

Phase 1 Completed

HER2 Positive Breast Cancer

NCT04895579 2025-11-18

LCD

Phase 1 Completed

Carcinoma, Non-Small-Cell Lung

NCT04462471 2025-09-08

Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers

Phase 1 Completed

8 enrolled 8 charts

EndocrineHead & Neck

Thyroid cancer, follicular, Thyroid Cancer, Papillary, Thyroid Neoplasms

NCT03735628 2023-10-06

An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors

Phase 1 Completed

GastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular

NCT03517956 2022-07-14

ROCOCO

Phase 1 Completed

Neoplasm Metastasis

NCT03498430 2021-05-19

Copanlisib Chinese PK Study

Phase 1 Completed

Lymphoma, Non-Hodgkin

NCT03172884 2021-04-28

Study of Copanlisib in Hepatic or Renal Impairment

Phase 1 Completed

30 enrolled 20 charts

Hepatic Insufficiency, Renal Insufficiency

NCT02253420 2020-12-14

COPANLISIB (BAY80-6946) Drug-drug Interaction and Cardiovascular Safety Study in Advanced Solid Tumor and Non-Hodgkin's Lymphoma Patients

Phase 1 Completed

Lymphoma, Non-Hodgkin

NCT01411410 2017-10-11

Phase I Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With Paclitaxel in Patients With Advanced Cancer

Phase 1 Completed

Neoplasms

NCT00962611 2017-10-06

BAY80-6946 Open Label, Phase I Study in Patients With Advanced Cancer

Phase 1 Completed

Neoplasms

NCT02155582 2017-06-16

Copanlisib Pharmacodynamic Study

Phase 1 Completed

Lymphoma, Non-Hodgkin

NCT01392521 2015-04-17

Phase Ib Study of PI3(Phosphoinositol 3)-Kinase Inhibitor Copanlisib With MEK (Mitogen-activated Protein Kinase) Inhibitor Refametinib (BAY86-9766) in Patients With Advanced Cancer

Phase 1 Completed

Neoplasms